ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in San Francisco, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Brain Diseases
Psychomotor Agitation
Nervous System Diseases

Alzheimer's Disease trials near San Francisco, CA, USA:

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...

Enrolling
Early Alzheimer's Disease
Drug: Placebo
Drug: CT1812

Phase 2

Cognition Therapeutics
Cognition Therapeutics

Palo Alto, California, United States and 29 other locations

This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease...

Active, not recruiting
Alzheimer Disease
Dementia of Alzheimer Type
Drug: Placebo
Drug: ATH-1017

Phase 2, Phase 3

Athira Pharma
Athira Pharma

Lafayette, California, United States of America and 89 other locations

progression of AD, as compared to no stimulation (OFF), by measuring baseline (pre-implantation) to 12-month change in the integrated Alzheimer's...

Active, not recruiting
Alzheimer Disease
Device: DBS-f On
Device: DBS Off
Functional Neuromodulation

Stanford, California, United States and 20 other locations

The investigators will study performance on computerized cognitive tasks in healthy participants of different ages to gather normative data for newly...

Enrolling
Alzheimer Disease
Aging
Diagnostic Test: California Cognitive Assessment Battery
Neurobehavioral Systems

Berkeley, California, United States

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

San Francisco, California, United States and 117 other locations

versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Other: Placebo
Biological: Bepranemab

Phase 2

UCB
UCB

Palo Alto, California, United States and 102 other locations

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo
Drug: Lecanemab

Phase 3

Eisai
Eisai

San Francisco, California, United States of America and 246 other locations

The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: ATH-1017

Phase 2, Phase 3

Athira Pharma
Athira Pharma

Lafayette, California, United States of America and 75 other locations

study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's...

Enrolling
Alzheimer Disease, Early Onset
Other: Placebo
Drug: BMS-986446

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

San Francisco, California, United States and 202 other locations

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: AR1001

Phase 3

AriBio

Burlingame, California, United States and 99 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems